{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:27:38Z","timestamp":1793662058293,"version":"4.5.1"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To study the safety of extended monthly intravitreal infliximab injections in patients with active posterior uveitis in Behcet's disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This is a prospective, interventional, noncomparative, open-label, pilot study of 9 monthly intravitreal infliximab injections (1 mg\/0.05 mL) for 22 eyes of 16 patients with active posterior uveitis in Behcet's disease. Control of inflammation and visual outcomes were assessed, and ocular complications were monitored during the study period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Successful treatment was achieved in 7 eyes (35%), and failure was encountered in 13 eyes (65%). Only seven eyes of six patients (35%) had completed the study and achieved complete resolution of inflammation with improved best-corrected visual acuity and no complications. Failure was either because of inability to control the inflammation in nine eyes (45%) or development of exacerbation of inflammation in four eyes (20%). Four eyes developed severe immunological reaction from the drug after first (n = 1), second (n = 2), and third (n = 1) injections and had to discontinue the injections. Kaplan\u2013Meier survival analysis showed that the mean estimated time to failure was 3.3 \u00b1 0.2 months, and all failed eyes required revision of their systemic immunotherapy to control the ocular inflammation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Intravitreal infliximab for active posterior uveitis in Behcet's disease was associated with a high complication rate and failure to control inflammation in most eyes. It should not be considered a substitute to systemic therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003095","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T23:30:07Z","timestamp":1609457407000},"page":"1739-1747","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":23,"title":["MONTHLY INTRAVITREAL INFLIXIMAB IN BEH\u00c7ET'S DISEASE ACTIVE POSTERIOR UVEITIS"],"prefix":"10.1097","volume":"41","author":[{"given":"Mohammad","family":"Refaat","sequence":"first","affiliation":[{"name":"Ophthalmology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdussalam M.","family":"Abdullatif","sequence":"additional","affiliation":[{"name":"Ophthalmology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa M.","family":"Hamza","sequence":"additional","affiliation":[{"name":"Ophthalmology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer A.","family":"Macky","sequence":"additional","affiliation":[{"name":"Ophthalmology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed-Sameh H.","family":"El-Agha","sequence":"additional","affiliation":[{"name":"Ophthalmology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaafar","family":"Ragab","sequence":"additional","affiliation":[{"name":"Internal Medicine, Kasr El Aini Hospital, Cairo University, El-Manial, Cairo, Egypt."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M.","family":"Soliman","sequence":"additional","affiliation":[{"name":"Ophthalmology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250607","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0049-0172(98)80001-2","article-title":"Beh\u00e7et's disease","volume":"27","author":"Kaklamani","year":"1998","journal-title":"Semin Arthritis Rheum"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","article-title":"Beh\u00e7et's disease","volume":"341","author":"Sakane","year":"1999","journal-title":"N Engl J Med"},{"key":"R3-20250607","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","article-title":"Uveitis in Beh\u00e7et disease: an analysis of 880 patients","volume":"138","author":"Tugal-Tutkun","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R4-20250607","first-page":"619","article-title":"TNF and TNFR biology in health and disease","volume":"47","author":"McDermott","year":"2001","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00347-010-2256-y","article-title":"Anti-TNF-\u03b1 treatment for uveitis. Analysis of the current situation","volume":"108","author":"Pleyer","year":"2011","journal-title":"Ophthalmologe"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3109\/09273940903072443","article-title":"Clinical review: anti TNF alpha therapies in uveitis: perspective on 5 years of clinical experience","volume":"17","author":"Sharma","year":"2009","journal-title":"Ocul Immunol Inflamm"},{"key":"R7-20250607","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1089\/jop.2011.0199","article-title":"Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis","volume":"28","author":"Farvardin","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ajo.2012.03.035","article-title":"Intravitreal infliximab for sight-threatening relapsing uveitis in Beh\u00e7et disease: a pilot study in 15 patients","volume":"154","author":"Markomichelakis","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1097\/IAE.0000000000001109","article-title":"Intravitreal infliximab in refractory uveitis in Beh\u00e7et's disease: a safety and efficacy clinical study","volume":"36","author":"Hamza","year":"2016","journal-title":"Retina"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/IAE.0b013e3181bcef3b","article-title":"Adverse events after intravitreal infliximab (Remicade)","volume":"30","author":"Giganti","year":"2010","journal-title":"Retina"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1097\/IAE.0b013e3181e9f942","article-title":"Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy","volume":"30","author":"Arias","year":"2010","journal-title":"Retina"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1089\/jop.2012.0203","article-title":"Intravitreal tumor necrosis factor-alpha inhibitors for neovascular age-related macular degeneration suboptimally responsive to anti-vascular endothelial growth factor agents: a pilot study from the Pan American Collaborative Retina Study Group","volume":"29","author":"Wu","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Beh\u00e7et's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","author":"Davatchi","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"Update of the EULAR recommendations for the management of Beh\u00e7et's syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1590\/S0004-27492011000500009","article-title":"A safety study of retinal toxicity after serial intravitreal injections of infliximab in rabbits eyes","volume":"74","author":"Rassi","year":"2011","journal-title":"Arq Bras Oftalmol"},{"key":"R19-20250607","first-page":"319","article-title":"Intravitreal adalimumab in active noninfectious uveitis: a pilot study","volume":"24","author":"Hamam","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/15569527.2019.1632883","article-title":"The efficacy of systemic and intravitreal infliximab treatments in an endotoxin-induced uveitis model","volume":"38","author":"Donmez","year":"2019","journal-title":"Cutan Ocul Toxicol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T18:04:04Z","timestamp":1749319444000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003095"}},"subtitle":["A Long-Term Safety Study"],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003095","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]}}}